PT835309E - VACCINE AGAINST INFECTIOUS AGENTS COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS - Google Patents

VACCINE AGAINST INFECTIOUS AGENTS COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS

Info

Publication number
PT835309E
PT835309E PT96924033T PT96924033T PT835309E PT 835309 E PT835309 E PT 835309E PT 96924033 T PT96924033 T PT 96924033T PT 96924033 T PT96924033 T PT 96924033T PT 835309 E PT835309 E PT 835309E
Authority
PT
Portugal
Prior art keywords
pct
hiv infections
prevention
treatment
infectious agents
Prior art date
Application number
PT96924033T
Other languages
Portuguese (pt)
Inventor
Jean-Claude Chermann
Carole Le Contel
Pascale Galea
Original Assignee
Inst Nat S Et De La Rec Medi I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat S Et De La Rec Medi I filed Critical Inst Nat S Et De La Rec Medi I
Publication of PT835309E publication Critical patent/PT835309E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PCT No. PCT/FR96/01006 Sec. 371 Date Feb. 19, 1997 Sec. 102(e) Date Feb. 19, 1997 PCT Filed Jun. 28, 1996 PCT Pub. No. WO97/02344 PCT Pub. Date Jan. 23, 1997An immunogenic composition for treating and/or preventing infectious diseases where the infectious agent has at least one intracellular phase in the host during its multiplication cycle, is disclosed. The immunogenic composition comprises at least one cryptic epitope of a cellular element that is carried along by an intracellular infectious agent as it leaves the cell, and revealed by said infectious agent. A composition for treating and/or preventing HIV infections, antibodies to a peptide of interest, and a diagnostic method, are also disclosed.
PT96924033T 1995-06-30 1996-06-28 VACCINE AGAINST INFECTIOUS AGENTS COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS PT835309E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9507914A FR2735984B1 (en) 1995-06-30 1995-06-30 VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, ANTIBODIES AND DIAGNOSTIC METHOD

Publications (1)

Publication Number Publication Date
PT835309E true PT835309E (en) 2002-03-28

Family

ID=9480577

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96924033T PT835309E (en) 1995-06-30 1996-06-28 VACCINE AGAINST INFECTIOUS AGENTS COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS

Country Status (13)

Country Link
US (1) US6113902A (en)
EP (1) EP0835309B1 (en)
JP (1) JP4036895B2 (en)
CN (1) CN1117148C (en)
AT (1) ATE206456T1 (en)
AU (1) AU6462396A (en)
CA (1) CA2223825A1 (en)
DE (1) DE69615685T2 (en)
DK (1) DK0835309T3 (en)
ES (1) ES2165510T3 (en)
FR (1) FR2735984B1 (en)
PT (1) PT835309E (en)
WO (1) WO1997002344A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
FR2836146B1 (en) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULIN IgG3 PROTECTIVE MARKER FOR INFECTIOUS VIRAL DISEASES AND USES THEREOF
DE60332481D1 (en) * 2002-12-06 2010-06-17 Zhi Cheng Xiao PEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
TW200846363A (en) * 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
EP2374470A1 (en) * 2010-04-08 2011-10-12 Beta Innov Therapeutic use of the Beta2m protein
EP3512551A4 (en) * 2016-09-16 2020-08-05 The Brigham and Women's Hospital, Inc. Blockade of alphafetoprotein (afp) interactions with beta2-microglobulin associated molecules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK160944C (en) * 1986-01-16 1991-10-21 Novo Industri As MODIFIED BETA2 MICROGLOBULINES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
US5733550A (en) * 1990-05-10 1998-03-31 Dana-Farber Cancer Institute, Inc. Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin
FR2675508A1 (en) * 1991-04-18 1992-10-23 Tm Innovation COMPOUND COMPRISING A PEPTIDE SEQUENCE NEUTRALIZING HUMAN CYTOMEGALOVIRUS (HCMV) INFECTION AND COMPOSITION COMPRISING SAME.
GB9201023D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Vaccines
GB9214871D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Vaccines
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
GB9307371D0 (en) * 1993-04-08 1993-06-02 Walls Alan J Fusion proteins

Also Published As

Publication number Publication date
DE69615685D1 (en) 2001-11-08
ATE206456T1 (en) 2001-10-15
DK0835309T3 (en) 2002-12-02
EP0835309B1 (en) 2001-10-04
EP0835309A2 (en) 1998-04-15
WO1997002344A3 (en) 1997-03-06
WO1997002344A2 (en) 1997-01-23
US6113902A (en) 2000-09-05
DE69615685T2 (en) 2002-08-08
JP4036895B2 (en) 2008-01-23
FR2735984B1 (en) 1997-09-19
JPH11509407A (en) 1999-08-24
ES2165510T3 (en) 2002-03-16
CA2223825A1 (en) 1997-01-23
CN1117148C (en) 2003-08-06
FR2735984A1 (en) 1997-01-03
CN1193349A (en) 1998-09-16
AU6462396A (en) 1997-02-05

Similar Documents

Publication Publication Date Title
PT1296711E (en) E7 FOR THE TREATMENT OF HUMAN PAPILOMA VIRUS
DE69133516D1 (en) TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTO ATIGENIGEN
NO994256D0 (en) Small molecules useful in the treatment of inflammatory disease
BG95935A (en) METHOD AND AGENT FOR ADMINISTERING DEXMEDETOMIDINE DIRECTLY THROUGH THE SKIN
LU91928I2 (en) Ipilimumab and its pharmaceutically acceptable derivatives (YERVOY®)
DE69332643D1 (en) HUMAN, NEUTRALIZING, MONOCLONAL ANTIBODIES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
DK55891A (en) MATRIX WITH IMMUNO MODULATIVE EFFECT
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
DE69720056D1 (en) CHLAMYDIA VACCINALS AND IMMUNOGENIC CHLAMYDIA COMPOSITIONS CONTAINING AN ANTIGUE OF THE OUTER MEMBRANE AND METHOD FOR THE PRODUCTION THEREOF
ATE179614T1 (en) HERPES SIMPLEX VIRUS VP16 VACCINES
ES2173923T3 (en) PROCEDURE THAT ALLOWS TO INACTIVATE A VIRUS IN THE PRESENCE OF A POLIETER AND AN AGENT.
PT835309E (en) VACCINE AGAINST INFECTIOUS AGENTS COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS
MX9101958A (en) AMINOSULFONYL UREA ACAT INHIBITORS
NO962655L (en) Deuterated active substances in transdermal application
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
FR2735026B1 (en) HAIR COMPOSITION COMPRISING MYRTLE EXTRACT, ITS PREPARATION METHOD AND ITS USE IN PARTICULAR FOR ANTI-DANDRUFF TREATMENT.
NZ294878A (en) Water soluble derivatives of epipodophyllotoxin and medicaments
DK0821593T3 (en) Conjugate of an active agent, a protein and, optionally, a non-foreign native protein considered by the body
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
SE9400524D0 (en) energy Preparations
WO2000063386A3 (en) Prevention, diagnosis and treatment of lyme disease
DE3373978D1 (en) Composition for the care or treatment of the human skin
EP0836480A4 (en) Compositions exhibiting adp-ribosyltransferase activity and methods for the preparation and use thereof
IT1276453B1 (en) HELYCOBACTER PYLORI VACCINE/THERAPEUTIC COMPOSITIONS, THEIR PREPARATION AND USE.
UA32241A (en) Method for treating inflammations in experiment